{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000349","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.703170+00:00","generated_at":"2026-06-29T01:32:45.036181+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regen Biopharma secures $1.39M net financing via $1.5M note, settles ChemDiv lawsuit for $800K","bullets":["Issued $1.5M promissory note to Coventry Enterprises LLC; net proceeds $1.39M after $75K OID and $35K fees.","Note carries 5% guaranteed interest, matures July 2022, convertible only upon default.","Paid $800K to ChemDiv to settle lawsuit; settlement includes release of claims and protects IP.","CEO David Koos reports progress: current SEC filings, $1.905M licensing revenue in Q2 2021, revived patents.","Goals include settling all convertible notes, hiring CSO, and seeking OTCQB listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000349","json":"https://secwatch.observer/filing/0001607062-21-000349.json","markdown":"https://secwatch.observer/filing/0001607062-21-000349.md","text":"https://secwatch.observer/filing/0001607062-21-000349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000349/0001607062-21-000349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000349/rgbp092421form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:32:45.036181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}